Top Suppliers:I want be here
  • DC Chemicals Limited
  • China
  • Product Name: TAI-1
  • Price: $400.0/100mg $800.0/250mg $1500.0/1g
  • Purity: 98.0%
  • Stocking Period: 3 Day
  • Contact: Tony Cao

1334921-03-7

1334921-03-7 structure
1334921-03-7 structure
  • Name: TAI-1
  • Chemical Name: N-{4-[4-(4-methoxyphenoxy)-2,6-dimethylphenyl]thiazol-2-yl}pyridine-4-carboxamide
  • CAS Number: 1334921-03-7
  • Molecular Formula: C24H21N3O3S
  • Molecular Weight: 431.50700
  • Catalog: Biochemical Inhibitor Cytoskeletal Signaling Microtubule Associated Inhibitor
  • Create Date: 2018-03-20 22:09:49
  • Modify Date: 2024-01-04 17:58:13
  • TAI-1, an orally active anticancer agent, is a highly potent first-in-class Hec1 inhibitor, with a GI50 of 13.48 nM in K562 cells[1].

Name N-{4-[4-(4-methoxyphenoxy)-2,6-dimethylphenyl]thiazol-2-yl}pyridine-4-carboxamide
Synonyms N-(4-(4-(4-methoxyphenoxy)-2,6-dimethylphenyl)thiazol-2-yl)isonicotinamide
TAI-1
Description TAI-1, an orally active anticancer agent, is a highly potent first-in-class Hec1 inhibitor, with a GI50 of 13.48 nM in K562 cells[1].
Related Catalog
Target

GI50: 13.48 nM (in K562 cells)[1].

In Vitro TAI-1 disrupts Hec1-Nek2 protein interaction, leads to Nek2 degradation, induces significant chromosomal misalignment in metaphase, and induces apoptotic cell death[1]. TAI-1 induces cancer cell death through the induction of cleavage of apoptotic proteins Caspase 3 and PARP and degradation of anti-apoptotic proteins MCL-1 and suggests that TAI-1 leads to activation of the apoptotic pathways[1]. TAI-1 is effective in many cancer cells, such as Chronic myeloid leukemia, Cervical cancer, Breast, metastatic-pleural, invasive ductal carcinoma, Acute myeloid leukemia, Myelogenous leukemia, Colorectal carcinoma cells, with GI50 less than 100 nM[1].
In Vivo TAI-1 (20 mg/kg intravenously IV/ or 150 mg/kg per oral PO/BID) inhibits tumor growth in multiple cancer xenograft models[1]. Animal Model: C.B-17 SCID mice (6-7 weeks, 21-24 g)[1]. Dosage: 20 mg/kg intravenously IV/ or 150 mg/kg per oral PO/BID. Administration: QDx28 cycles. Result: Led to significant tumor growth retardation in Huh-7 and modest tumor inhibition was noted tor the Colo205 and MDA-MB-231 models. Did not lead to any loss in body weight.
References

[1]. Lynn Y L Huang, et al. Characterization of the Biological Activity of a Potent Small Molecule Hec1 Inhibitor TAI-1. J Exp Clin Cancer Res. 2014 Jan 9;33(1):6.

Molecular Formula C24H21N3O3S
Molecular Weight 431.50700
Exact Mass 431.13000
PSA 101.58000
LogP 5.94810
Storage condition -20℃